This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Myron H. Luria, MD

Arch Intern Med. 1988;148(11):2493-2495.

Abstract
• Niacin significantly alters blood lipid concentrations but its use has been limited because of clinically disturbing side effects. In an attempt to circumvent these drawbacks, 55 patients with cardiovascular disease were given low-dose long-acting niacin, 1 g/d. Treatment was continued for a mean of 6.7 months and lipid values were compared with a nontreated group of 17 patients followed for a mean of 6.3 months. Lipid values did not change in the nontreated group. In the niacin-treated group total cholesterol and triglyceride levels also did not significantly change. High-density lipoprotein (HDL) cholesterol level rose 31% from 1.01 ±0.31 mmol/L to 1.32±0.31 mmol/L and total cholesterol/HDL cholesterol ratio was reduced 27% from 6.4±1.9 to 4.7±1.3. Despite these results, 40% of the patients left the study mainly because of side effects. Apart from one patient who developed overt diabetes, of questionable relationship to niacin, no patient developed serious side effects such as jaundice or peptic ulcer as seen with much higher doses of the drug. Although often difficult to administer to patients, niacin, particularly in low dose, deserves consideration as an inexpensive agent especially useful for elevating HDL cholesterol level and altering the total cholesterol/HDL cholesterol ratio.

(Arch Intern Med 1988;148:2493-2495)

Author Affiliations
From the Division of Cardiology, Department of Medicine, St Luke's Hospital, and Case Western Reserve University School of Medicine, Cleveland. Dr Luria is presently with the Department of Cardiology, Hadassah Hospital, Jerusalem.

Footnotes
Accepted for publication June 30, 1988.

Reprint requests to Department of Cardiology, Hadassah Hospital, PO Box 12000, 91120 Jerusalem, Israel (Dr Luria).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Niacin as a Component of Combination Therapy for Dyslipidemia
Miller
Mayo Clin Proc. 2003;78:735-742.
ABSTRACT  

Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim and Chong
The Annals of Pharmacotherapy 2003;37:106-115.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Clinical Trial of Wax-Matrix Sustained-Release Niacin in a Russian Population With Hypercholesterolemia
Aronov et al.
Arch Fam Med 1996;5:567-575.
ABSTRACT  

Effectiveness of Low-Dose Crystalline Nicotinic Acid in Men With Low High-Density Lipoprotein Cholesterol Levels
Martin-Jadraque et al.
Arch Intern Med 1996;156:1081-1088.
ABSTRACT  

Discontinuation of Antihyperlipidemic Drugs -- Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
Andrade et al.
NEJM 1995;332:1125-1131.
ABSTRACT | FULL TEXT  

Patient-Directed, Nonprescription Approaches to Cardiovascular Disease
Simon
Arch Intern Med 1994;154:2283-2296.
ABSTRACT  

A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
McKenney et al.
JAMA 1994;271:672-677.
ABSTRACT  

Lipoprotein Responses to Treatment With Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients With Hypoalphalipoproteinemia
Vega and Grundy
Arch Intern Med 1994;154:73-82.
ABSTRACT  

Low Levels of High-Density Lipoprotein Cholesterol (Hypoalphalipoproteinemia) An Approach to Management
Rosenson
Arch Intern Med 1993;153:1528-1538.
ABSTRACT  

Niacin Revisited: A Randomized, Controlled Trial of Wax-Matrix Sustained-Release Niacin in Hypercholesterolemia
Keenan et al.
Arch Intern Med 1991;151:1424-1432.
ABSTRACT